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Purpose: Pharmaceutical care (PC) is still a theoretical statement in Nigeria and not 
operational. The goal of this study is to identify practice standards that can be effectively 
applied in the implementation of pharmaceutical care in Nigeria. 
Method: The survey instrument (a pre-tested self-administered questionnaire) was distributed 
to pharmacists in Benin City. Each questionnaire contained the 52 suggested practice 
standards obtained from round one discussion by the Delphi panel of PC experts. The 
pharmacists were requested to indicate in the questionnaire whether or not each of the 
standards was feasible, relevant, being currently applied or intend to be apply it in their 
practice setting. Analysis of the responses on “being currently applied or intend to apply it” 
excluded the pharmacists in academia since nearly all of them were full-time University 
Lecturers.  
Result: Of the 150 copies of the questionnaire distributed, 119 (79.3%) responded. The 
average proportion of pharmacists who gave positive response to each of the standards were 
as follows: feasibility (71.3% ± 9.2%), relevance (72.0% ± 8.0%), currently apply it (18.2% ± 
20.2%) and intend to apply it (10.8% ± 6.7%). The 95% confidence intervals of the responses 
were: feasibility (68.7% – 73.9%), relevance (69.7% - 74.4%), currently apply it (12.5% - 
23.8%), and intend to apply it (8.9% - 12.6%). Neither the age, years of professional 
experience, qualification nor area of practice significantly influenced the pharmacists 
responses. Forty-seven (47) of the 52 standards were identified for application by the 
pharmacists. 
Conclusion: PC standards that can be effectively applied in improving effective 
pharmaceutical services in Benin City have been identified. The identified 47 standards are 
most likely to stimulate the widespread implementation of PC in Nigeria if seriously addressed 
by the Pharmacists Council of Nigeria, the Pharmaceutical Society of Nigeria and Nigeria 
pharmacists. 
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Introduction 
 
Pharmaceutical care is a process in which a 
pharmacist co-operates with a patient and 
other professionals in designing, 
implementing and monitoring a therapeutic 
plan that will produce specific therapeutic 
outcomes for the patient. These outcomes 
are: cure of a disease, elimination or 
reduction of a patient’s symptoms, arresting 
or slowing a disease process or preventing a 
disease or symptoms1. Pharmaceutical care 
involves identifying, resolving and preventing 
drug-related problems. Since it was first 
defined by Hepler and Strand1 in 1990 as 
“the responsible provision of drug therapy for 
the purpose of achieving definite outcomes 
that improve a patient’s quality of life, the 
care has taken on a wide variety of 
meanings to researchers and pharmacy 
practitioners and the operational definition 
range from the mandatory counseling to 
patient assessment and the development of 
patient care plans2. Many more definitions 
have now emerged and Cipolle and his 
colleagues have redefined it as “a practice in 
which the practitioner takes responsibility for 
a patient’s drug-related needs and is held 
accountable for this commitment3. This latter 
definition has three components which are: 
(1) a philosophy of practice, (2) a patient 
care process, and (3) a practice 
management system. Most major pharmacy 
organizations in developed countries (e.g., 
the American Pharmaceutical Association 
[AphA]4 and the American Society of Health-
System Pharmacists5) have since adopted 
the pharmaceutical care philosophy.  
 
Pharmaceutical care evolved from clinical 
pharmacy practice (which evidently emerged 
in Nigeria in the 1980’s with the introduction 
of clinical pharmacy courses in the Faculty of 
Pharmacy, University of Benin, Benin City). 
The philosophy has achieved great 
successes in the care of patients in the 
United States and elsewhere. Patients now 
get better care from pharmacists, and the 
pharmacists, the patients and health care 
managers are delighted about the initiative. 
However, among the pharmacists in Nigeria, 
pharmaceutical care is often discussed in 
continuing professional education 
programmes and in conferences, and it is 
only yet considered as a model that needs to 
be implemented in the health care system.  
 
Admittedly, the standard of pharmacy 
practice in Nigeria is not the same as it is in 
most other countries. If nothing else, the 
practice settings are different. One of the 
interesting things about health care in 
Nigeria is that private patients entering the 
hospitals have to pay for their own food, 
bedding, bandages, medical supplies, drugs 
and other products essential to proper care 
and healing. In many cases, patients or their 
families have no money to pay for drugs and 
other necessities. Other factors that are 
potential barriers to pharmaceutical care are 
those already identified and include: (1) not 
enough time to talk with patients, (2) lack of 
private counseling area in the pharmacy, (3) 
inadequate training, (4) pharmacist’s 
perception that patients are not willing to pay 
for this intensive level of care and (5) 
trepidation regarding the reaction of 
physicians6-10. These factors are not only 
compromising the early implementation of 
pharmaceutical care in hospitals and 
community pharmacies in Nigeria but have 
also had negative consequences on the 
impact of clinical pharmacy practice in the 
health care system in the country. Despite 
these problems, pharmaceutical care poses 
great challenges before the pharmacy 
profession in Nigeria.  The challenges need 
to be addressed in order to move the care 
from a theoretical statement in Nigeria (as it 
is now) to an operational level.   
If all pharmacists are expected to universally 
deliver pharmaceutical care, they should 
adopt practice standards that provide 
meaning to the term and enable a holistic 
view of patient care. The answer to a 
fundamental question on whether the 
standards should be consistent regardless of 
various practice settings is that although the 
goals of pharmaceutical care exist 
independent of practice setting, the specific 
content of standards may vary from setting 
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to setting1. Also, lack of standards for 
pharmacists to conform to in daily practice 
has been identified as a primary obstruction 
to widespread implementation of 
pharmaceutical care2. Already, a Delphi 
panel of pharmaceutical care experts has 
suggested 52 practice standards2 upon 
which a consensus was arrived at in the 
United States. This opens a lead way for the 
identification of standards that can effectively 
be applied in pharmacy practice in Nigeria. 
 
The primary intent of this study was to 
identify standards that can be effectively 
applied in implementing pharmaceutical care 
practice in Nigeria. The specific objectives 
are (1) to identify pharmaceutical care 
practice standards that can be effectively 
applied in Benin City, and (2) assess which 
of the practice standards are feasible, 
relevant and currently being applied or 
intended to be applied in Benin City. With the 
introduction of the Doctor of Pharmacy 
programmes in the training of pharmacists in 
Nigeria (which has already taken-off in the 
University of Benin, Benin City), the outcome 
of this study should create new knowledge 
with both theoretical and practical 
implications. In addition to reporting opinions 
or judgements, the study will provide a basis 
for changes in pharmacy practice and a 
framework for the implementation of 




This study was carried out in Benin City, a 
large metropolitan city located in the south-
south geopolitical zone of Nigeria. The city 
has a projected population of about 1.2 
million. There are three tertiary health care 
facilities; a 550-bed University of Benin 
Teaching Hospital (UBTH), a 400-bed Edo 
State Government controlled Specialist 
Hospital and a Psychiatric Hospital. Each of 
these facilities has pharmacy departments 
under the control of registered pharmacists. 
There is also a Military Hospital and at least 
150 registered community pharmacies, 
providing pharmaceutical services to the 
population under the supervision of 
pharmacists. At the time of this study 
(January to June 2002), there were about 
211 registered pharmacists in Benin City. 
There are several other health care facilities 
including private hospitals, doctor’s clinics or 
surgeries, maternity homes and herbal 
homes where pharmaceutical services are 
not being provided by qualified pharmacists. 
In all the health care facilities, the 
pharmaceutical care practice is not currently 
being effectively applied and clinical 
pharmacy practice is only marginally evident 
in the tertiary health care facilities. Apart 
from one community pharmacy where 
clinical pharmacy practice is obvious, all the 
community pharmacies engage in traditional 
drug retailing and distribution. 
 
The survey instrument (pre-tested self-
administered questionnaire) for this study 
was constructed based on the 52 suggested 
practice standards obtained from the round 
one discussion by the Delphi panel of 
pharmaceutical care experts (see 
Appendix)2. The questionnaire contained the 
initial 52 suggested practice standards with 
spaces provided for indicating age, gender, 
qualification, practice area and year of 
experience, and whether each standard was 
feasible or not feasible, relevant or not 
relevant, currently applied in his/her 
establishment or not currently applied, and 
there was plan to implement it in his/her 
establishment or not. One hundred and fifty 
(150) copies of the questionnaire were 
distributed to qualified pharmacists who were 
in academics, hospital practice or community 
practice. Academic pharmacists were 
included in this study because they are 
involved in the training of pharmacy 
undergraduates and continuing professional 
education of qualified pharmacists. They are 
also frequently involved in the development 
of guidelines and standards of practice in 
pharmacy. The questions were distributed to 
the pharmacists in their offices. The 
researchers discussed the purpose of the 
study with each of the participating 
pharmacists, and educated them on the 
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questionnaire format and how to indicate the 
desired response in the appropriate space 
provided in the questionnaire in order to 
prevent errors in responses. The copies of 
the questionnaire were left with the 
pharmacists who voluntarily accepted to 
participate in the study and retrieved from 
them within a period of two weeks after one 
to three visits. Those who were unable to fill 
the questionnaire by the third visit were 
considered as non-respondents because of 
time considerations.  
 
Each questionnaire used in this study was 
coded for easy reference. The responses 
from the study were fed into computer 
software, Epi Info 2000 (CDC, USA/WHO, 
Geneva) and double-checked to ensure 
accurate data entry. The data were analysed 
in terms of demographic characteristics, 
professional experience, qualification and 
practice areas (academic, hospital or 
community practice) using frequencies and 
percentages as appropriate. In analyzing the 
responses on current application and 
intention to apply the practice standards, 
only responses from pharmacists working in 
hospitals and community pharmacies were 
considered. This approach was adopted to 
prevent bias as nearly all the pharmacists in 
academia were full-time University Lecturers 
not involved in patient care. Chi-square test 
was adopted in estimating possible 
differences in proportions. Analysis of 
variance was used to determine differences 
between the age of the pharmacists, years of 
professional experience, qualification, 
practice areas and the responses to the 
suggested practice standards. For this 
purpose, the frequencies of responses for 
each suggested standard were determined 
based on age, years of experience, 
qualification and practice areas. At a 
confidence interval of 95%, a 2-tailed 
probability (p) value less than or equal to 
0.05 was considered to be 
significant..Statistical comparisons were 
made using a software called Instat 
(GraphPad Inc., USA). 
Result 
 
Of the 150 copies of the questionnaire 
distributed to the pharmacists, 119 
completed and returned the questionnaire, 
giving a response rate of 79.3%. All PhD 
holders were in academic setting and 
responded to the questionnaire. The age and 
sex distribution of the responding 
pharmacists are given in Table 1. A 
statistical gender balance was not achieved 
in this study (p < 0.04). The highest 
proportion (30.3%) of the respondents were 
aged from 31 – 40 years while the lowest 
proportion were in the age range of 51 – 60 
years.  
 
Table 1: Age and gender distribution of 
responding pharmacists 
 
Age (yr) Male (%) Female (%) 
21 - 30 18 (15.1) 15 (12.6) 
31 – 40 12 (10.1) 24 (20.2) 
41 – 50 18 (15.1) 10 (8.4) 
51 - 60 15 (12.6) 7 (5.9) 
      Total 63 (52.9) 56 (47.1) 
χ2 = 9.09, df = 3, p = 0.028 
 
The distribution of the respondents in 
respect of their qualifications, area of 
practice and years of experience are 
presented in Table 2. Majority of the 
respondents (71.6%) hold only a first degree 
in pharmacy. The rest had further higher 
education (master’s degree, fellowship and 
PhD). The highest proportion of the 
respondents practice in community 
pharmacies (47.8%) and had not more than 
five years experience as pharmacists. 
 
The positive responses to the 52 suggested 
practice standards are summarized in Table 
The positive responses to the 52 suggested 
practice standards are summarized in Table 
3. With respect to feasibility, the average 
positive response was 71.3%. Each of the 
practice standards with positive responses 
below 60% is marked with asterisk (*) in the 
Appendix (The 52 suggested practice 
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standards obtained from the round one 
Delphi procedure). The highest positive 
responses on feasibility were on the need for 
the pharmacist to (1) devise a standard 
system of data collection of all necessary 
medical and personal information from each 
patient (89.9%), (2) document follow-up care 
plan and where care plan is not deemed 
necessary (88.5%), and (3) formulate 
therapeutic plan for the patient (83.5%). 
On the question of the relevance of each of 
the practice standards, the average positive 
response (72.0%) was not significantly 
different from that of the responses for 
feasibility (p > 0.05). Not less than 50% of 
the pharmacists judged all the initial 52 
suggested practice standards to be both 
feasible and relevant. However, not less than 
60% of the pharmacists judged 47 of the 
Table 2: Distribution of respondents in respect of their qualification, area of practice and years of 
experience of responding pharmacists.  
 
Parameters Male (%) Female (%) 
Qualification    
Bachelor degree  36 (30.2) 41 (34.4) 
Bachelor and master’s degree in pharmacy 6  (5.0) 0 
Bachelor’s degree and master’s degree in business 
administration  
6 (5.0) 9 (7.6) 
Bachelor’s degree and master’s degree in health 
management and planning 
0 2 (1.6) 
Bachelor’s degree and PhD 13 (10.9) 3 (2.5) 
Bachelor’s degree and fellowship of West African 
Postgraduate College of Pharmacists 
2 (1.6) 1 (0.8) 
                           Total 63 (52.9) 56 (47.1) 
Practice Area Malea  Femalea 
Academics 14 (11.8) 3 (2.5) 
Community pharmacy 26 (21.8) 31 (26.0) 
Hospital 23 (19.3) 22 (18.5) 
                           Total 63 (52.9) 56 (47.1) 
Experience (yr) Maleb Femaleb 
1 – 5 21 (17.6) 18 (15.1) 
6 – 10 12 (10.1) 10 (8.4) 
11 – 15 6 (5.0) 8 (6.7) 
16 – 20 2 (1.6) 10 (8.4) 
> 20 22 (18.5) 10 (8.4) 
                           Total 63 (52.9) 56 (47.1) 
 aχ2 = 7.19, df = 3, p = 0.027;  bχ2 = 10.15, df = 4, p = 0.038 
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suggested practice standards to be both 
feasible and relevant. 
 
The responses on current application of 
each of the standards (mean ± sd, 18.2% ± 
20.2%; 95% confidence interval, 12.5% - 
23.8%) were generally low when compared 
with those of “relevance” and “feasibility”. 
The suggested standards currently applied 
by over 50% of the respondents are given in 
Table 4. Also, the responses on the intention 
to apply the standards in the respondents’ 
practice area were relatively low (mean ± sd, 
10.8% ± 6.7%; 95% confidence interval, 
8.9% - 12.6%). 
 
Table 3:  Average responses of pharmacists to the 52 suggested practice standards obtained from 












Feasibility 71.3 ± 9.2 68.7 – 73.9 50.6 – 89.9 
Relevance 72.0 ± 8.0 69.7 – 74.4 50.6 – 88.6 
Currently applied in my setting 18.2 ± 20.2 12.5 – 23.8 0 – 65.8 
Intends to implement the standard  10.8 ± 6.7 8.9 – 12.6 1.3 – 30.4 
 
 










1 The pharmacist shall make a conscious effort to provide oral patient 
counseling with each prescription that includes directions for use, 
indication, drug class, side effects, storage requirements, and what to 
do in case of missing a dose(s), in addition to providing a hard copy of 
this information 
56.9% 
2 The pharmacist will ask on each refill prescription the following 
question, "What problems are you having with this medicine?", or 
similar open-ended question 
 
54.4% 
3 Pharmacists shall have an area of private consultation available to 
patients  
63.3% 
4 When communicating with the patient, the pharmacist should use the 
open-ended question, "What questions do you have about this 
medication?" to address concerns and ensure patients understands 
their drug regimen 
 
53.2% 
5 The pharmacist will use large enough print on prescription labels to 
make them easily readable for patients in addition to frequently 
changing ribbons to ensure label readability 
 
50.6% 
6 The pharmacist should include written instructions to each patient on 
how to administer specialty products (i.e., ear drops, ophthalmic drops 
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In this study, analysis of variance did not 
reveal any significant difference between the 
years of experience, qualification, or practice 
areas and the responses to the suggested 




Drug therapy with prescribed medication is a 
collaborative process involving the patient, 
the physician, the pharmacist and other 
health care professionals. In recent years, 
pharmacists in many countries have adopted 
a much more patient centred approach in the 
pharmaceutical services they provide. This 
assures that both patient care and economic 
aspects of drug therapy are appropriately 
considered in the interest of the patient. The 
principles of pharmaceutical care are 
embedded in the concept of Good Pharmacy 
Practice11. Application of practice standards 
that are practicable can result in 
enhancement of clinical, economic and 
humanistic outcomes of patient care12-14. In 
arriving at practice standards that can be 
applied in Nigeria, this study has adopted 
this survey approach as a framework, using 
known standards that have been previously 
applied in arriving at practice standards 
elsewhere2.  
 
The need for pharmacists to agree on a 
standardized approach by which individual 
pharmacists will provide pharmaceutical care 
to patients cannot be overemphasized. 
There is no doubt that pharmaceutical care 
will fail if each pharmacy setting or individual 
pharmacists are allowed to define 
pharmaceutical care standards on their 
own15. The involvement of pharmacists in 
any setting in developing practice standards 
for pharmaceutical care to which they can 
adhere and upon which they may ultimately 
be evaluated is relevant2. It is for these 
reasons that only qualified pharmacists were 
involved in this study. Designed to provide a 
framework for developing standards that will 
be acceptable to pharmacists in Nigeria, and 
in particular, Benin City, and which they can 
meaningfully apply, this study has 
considered a good spread in the age, years 
of experience, qualification and practice 
areas as well as gender balance in its 
conduct. Although a statistically significant 
gender balance was not achieved in the 
study sample it is unlikely that the result 
obtained would change significantly if a 
gender balance was achieved. Neither the 
age, years of experience, qualification and 
practice areas was found to have 
significantly affected the responses from the 
responding pharmacists. The possible 
reason for this finding is that the introduction 
of the term, “pharmaceutical care” in the 
practice of pharmacy in Nigeria is new. 
Furthermore, pharmacists in Benin City are 
still trying to apply the philosophy with the 
hope that they will achieve a better health 
care provision.  
 
On the issue of feasibility and relevance of 
the Delphi initial 52 practice standards, it is 
difficult to recommend all the standards for 
initial application in Benin City even though 
more than 50% of the responding 
pharmacists have indicated the feasibility 
and relevance of all the standards. The 
practice standard numbers 32 and 33 in the 
Appendix which had positive responses 
between 50% and 60% were not judged 
feasible and relevant in a previous study2. 
Extension of this finding to the present study 
would justify the exclusion of all the practice 
standards with positive responses below 
60% (marked with asterisk [*] in the 
Appendix) from standards that can be 
recommended for use in Benin City, and in 
fact, Nigeria. The proximity of the 60% to the 
mean positive responses when compared 
with 50% further justifies the need for the 
exclusion. Thus, only the 47 standards in the 
Appendix without asterisk are being 
recommended for initial application in Benin 
City. Studies by Desselle and Rappaport2 on 
the initial 52 practice standards suggested 
by the Delphi Expert Panel indicated that 
only 43 of the standards were rated 
positively for feasibility and 50 of them were 
rated positive for relevance. The differences 
between some of the standards being 
identified in this study and those previously 
identified are not unexpected as 
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pharmaceutical care is at its infancy in 
Nigeria. Nevertheless, the similarity of most 
of the positively rated standards in the 
previous study2 to the 47 standards being 
recommended in this study is remarkable 
and supports the reliability of the outcome of 
this present study.  
 
Clearly, an adequate pharmaceutical service 
provided by pharmacists is a vital component 
of Primary Health Care. This is recognized 
by World Health Organization (WHO), and 
several publications emphasize the 
important role of the pharmacist in health 
care delivery16-18. A previous study19 has 
shown that pharmacists are generally 
positive about trying to provide 
pharmaceutical care but possess moderate 
to high intentions to apply the standards. 
Lack of workable strategies to adopt 
pharmaceutical care has been suggested as 
a possible reason for poor response on 
intention to apply the standards by many 
pharmacists19. The low positive response to 
current application and intention to apply the 
suggested standards in Benin City is 
contrary to report from the Netherlands 
where it is obvious that the pharmacists 
engage in many pharmaceutical care 
activities including health promotion and 
disease prevention, patient counseling and 
communication with other health 
professionals20. The current low application 
and intention to apply the practice standards 
in hospitals and community pharmacies is 
predictable. Pharmacists in Benin City, and 
in fact, most other parts of Nigeria, still 
practice in health care environments where 
there are little or no spaces provided for 
patient counseling. The medical profession 
has recently become hostile with the concept 
of clinical practice by pharmacists.   Also, 
most of the pharmacists frequently 
demonstrate lack of confidence and 
assertiveness needed to effectively carry out 
their clinical roles in hospitals. Furthermore, 
the provision of pharmaceutical care is not 
merely a function of individual decision-
making but is strongly impacted by 
pharmacists’ perceived control over their 
practice environments21. These facts may 
account for the low positive response on 
current application and intention to apply the 
pharmaceutical care standards. This calls for 
urgent attention by the Pharmaceutical 
Society of Nigeria, the Pharmacists Council 
of Nigeria (the regulatory organ of the 
practice of pharmacy in Nigeria) and all 
pharmacists practicing in Nigeria, to 
seriously address the needs of patients, and 
better health care for them through effective 
pharmaceutical services. The pharmacists in 
Nigeria should be made aware of this 
obligation. Challenges posed by the low 
positive responses on the current application 
and intention to apply each of the standards 
demand an early development and 
implementation of guidelines and standards 
for pharmaceutical care in Nigeria. Few 
pharmacists who currently apply some of the 
practice standards had clinical pharmacy 
training and work in hospitals and community 
pharmacies. 
 
The use of the suggested 52 practice 
standards in this study may have introduced 
bias as suggested in previous reports22-24. 
Nevertheless, many pharmacists in Benin 
City, and indeed Nigeria, are still not familiar 
with expected standards of practice of 
pharmaceutical care. This justifies the use of 




In addition to known factors affecting the 
implementation of pharmaceutical care in 
many countries (such as USA and Australia), 
the lack of pharmaceutical care practice 
standards applicable in Benin City, and in 
fact in Nigeria, is a major barrier to the 
implementation of pharmaceutical care in 
Nigeria. Pharmaceutical care practice 
standards that can be effectively applied in 
improving effective pharmaceutical services 
in Benin City have been identified. The 
identified 47 standards are most likely to 
stimulate the widespread implementation of 
pharmaceutical care in Nigeria if seriously 
addressed by the Pharmacists’ Council of 
Nigeria, the Pharmaceutical Society of 
Nigeria and Nigeria pharmacists. 
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Implementation of these standards will 
enable the patients and health care 
professionals to appreciate the value of the 
pharmaceutical care services in optimizing 
therapeutic and economic outcomes.  
The process of adopting innovation typically 
has several, significant stages of 
development and testing prior to adoption20. 
Thus, further studies would be needed to 
appraise and evaluate the standards with the 
aim of categorizing and simplifying them. 
This will hopefully provide a logical validity 
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The Fifty-Two Suggested Practice Standards  
Obtained From the Round One Delphi Procedure2 
 
1. The pharmacist shall devise a standard system of data collection of all necessary medical and 
personal information from each patient, including: prescribing physician(s), medication history, 
medical condition & diagnoses, allergies, and other data that would assist in detecting potential 
medical or drug-related problems. 
2 When potential problems are identified, a therapeutic plan should be formulated with the patient that 
becomes part his/her permanent record. This plan should be thoroughly discussed with the 
patient in addition to providing a hard (written) copy of the plan. 
3. The pharmacist should be prepared to re-evaluate and modify therapeutic plans on subsequent 
patient visits and consult with the necessary physician(s).  
4. The pharmacist should document each care plan and also document those occasions when a care 
plan is not deemed necessary. 
5. Follow-up appointments should be arranged within a reasonable time, preferably within 7-14 days 
of initial patient visit to assure positive outcomes (i.e., compliance, efficacy of drug regimen, 
avoidance of adverse reactions or drug interactions). 
6. The pharmacist will check each refill prescription for compliance (overuse, under-use, misuse, etc.) 
to assure positive outcomes. 
7. The pharmacist shall obtain access to each patient's lab tests, including diagnostic, HR, BP, weight, 
blood sugar, cholesterol, etc. where appropriate to record in the patient's record and assess 
trends in to determine the impact of drug therapy. 
8. Pharmacists should secure access to on-line medical libraries and medical literature as well as 
product literature & handouts from pharmaceutical companies. 
9. The pharmacist should regularly run reports on their patients to see if they are getting timely refills 
and visiting physicians on a scheduled basis, and intervene where appropriate.  
10. The pharmacist evaluates every prescription to detect any potential prescribing errors and 
intervenes when necessary.  
11. The pharmacist shall make a conscious effort to provide oral patient counseling with each 
prescription that includes directions for use, indication, drug class, side effects, storage 
requirements, and what to do in case of missing a dose(s), in addition to providing a hard copy of 
this information.  
12. The pharmacist maintains open and effective channels of communication with other health care 
providers for the benefit of the patient, mainly for the resolving of any potential or actual drug-
related problems. 
13. The pharmacist documents the results of each patient encounter and intervention. 
14. The pharmacist will assess and maintain a record of each patient's appropriate vital signs (i.e., 
blood pressure for hypertensives) to compare for future evaluation.  
15. When communicating with the patient, the pharmacist should use the open-ended question, "What 
questions do you have about this medication?" to address concerns and ensure patients 
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understands their drug regimen. 
16. The pharmacist will ask on each refill prescription the following question, "What problems are you 
having with this medicine?", or similar open-ended question. 
17. The pharmacist will regularly update all of the information in the patient's permanent pharmacy 
record.  
18. The pharmacist will use large enough print on prescription labels to make them easily readable for 
patients in addition to frequently changing ribbons to ensure label readability.  
19. The pharmacist should appropriately use technicians & other support personnel in clerical and 
dispensatory functions to create more time for patient interaction and patient care activities.  
20. The pharmacist shall obtain from each patient’s information regarding their use of any OTC 
medications with each visit and maintain this as part of their permanent pharmacy record.  
21. The pharmacist will make an effort to meet the major prescribers in the area to explain 
pharmaceutical care and let them know how he/she can help their patients with its 
implementation.  
22. The pharmacist should be actively involved with seeking and developing a relationship with a 
computer company that embraces the concept of pharmaceutical care and consistently develops 
new software to facilitate it.  
23. The pharmacist should strive to carry all products necessary to carry out a patient's drug therapy 
(i.e., nebulizers for asthma patients).  
*24. The pharmacist should attempt to professionalize pharmacy's product mix toward health-related 
items, such as products for nutrition & fitness and medical accessories.  
25. The pharmacist shall instruct all patients that have a disease that can be monitored and will 
discuss with these patients how to monitor them (diabetic blood glucose monitors, cholesterol 
tests, peak flow meters, etc.). 
26. The pharmacist should be actively involved in the promotion of community health and conduct 
seminars on health issues and disease management that include lifestyle modification, goal 
setting, and outcomes management.  
27. The pharmacist shall allow a specific amount of time for patients who wish to make appointments to 
discuss their care/care plans, health, or drug therapy. 
28. Pharmacists shall have an area of private consultation available to patients. 
29. Each pharmacist shall procure a certain amount of hours of continuing education on topics to 
enhance their abilities to document, intervene, and follow-up on patients.  
30. Pharmacists should be actively involved in support of associations and practice groups who 
promote the ideals of pharmaceutical care.  
31. Pharmacists shall promote the concept of pharmaceutical care to patients, physicians, benefits 
managers, and insurance companies.  
*32. The pharmacist shall follow-up via telephone with each patient started on a new antibiotic after 24-
72 hours of treatment to check for allergic reactions and therapeutic effect.  
*33. The pharmacist shall contact geriatric patients by telephone every three months to ensure 
compliance with cardiac and anti-hypertensive medications. 
34. The pharmacist shall be actively involved in the determination of the drug product formulary for their 
patients.  
35. Pharmacists should participate as principal investigators for IND's (investigational new drugs) and 
for proposed new indications of drugs.  
36. Pharmacists will utilize patient weight to determine and assure proper dosages of medications for 
children (< 12 years old or < 40 kg weight).  
*37. The pharmacy staff will phone patients who did not pick up new prescriptions within 1 day and refill 
prescriptions within 3 days after they have been filled to help ensure patients get their prescribed 
medication.  
38. Pharmacists who are made aware of adverse drug experiences by patients will complete a 
Medwatch report as part of the FDA's voluntary reporting program for ADR's.  
39. A compounding log will be prepared for each batch of compounded product prepared, which will 
include lot numbers of ingredients, dates of preparation & expiration, quantities used, and 
preparer's initials.  
40. The pharmacist should take an active role in all aspects of patient wellness. 
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*41. The pharmacist shall be the patient's advocate with regard to social, economical, and psychological 
barriers to drug therapy.  
42. The pharmacist should check for the most economical therapeutic alternative for any medication 
and relay this information to the prescriber.  
43. The pharmacist should include written instructions to each patient on how to administer specialty 
products (i.e., ear drops, ophthalmic drops and ointments, rectal suppositories, inhalers, 
injections, etc.)  
44. The pharmacist shall provide information to patients on special support and/or educational groups 
(such as the Multiple Sclerosis Society, American Diabetes Association, Vital Interest Program, 
etc.)  
45. The pharmacist shall exhibit competence and knowledge concerning the impact of OTC drugs on 
outcomes of disease states (e.g., use of niacin in Type II diabetics).  
46. The pharmacist shall triage the patient's OTC requests to determine if their problem requires 
referral, OTC treatment, or other supportive treatment and make individualized product 
recommendations for appropriate OTC requests. 
47. The pharmacist shall document OTC recommendations on the patient's profile. 
48. The pharmacist shall monitor the outcomes of OTC recommendations by a follow-up appointment 
or phone call.  
49. The pharmacist shall provide a written continuity of care report when a patient visits a new health 
care provider or new health care institution.  
50. The pharmacist shall ensure that complete prescription information is provided for patients unable 
to personally pick up their medications in addition to making a conscious effort to maintain 
updated medication profiles for these patients. 
51. The pharmacist should make efforts to optimize therapy and minimize effects by staying updated on 
common and newly discovered adverse effects and drug interactions, particularly with specific 
high-risk patients.  
52. The pharmacist should maintain a caring, friendly, responsible relationship with patients while 
taking a sincere interest in their health and drug therapy (e.g., asking, "How's your arthritis? 
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